Acute Myeloid Leukemia with Kmt2a Rearrangement
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia with Kmt2a Rearrangement.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene [Phase 1]
A Phase 1 clinical trial assessing adding SNDX-5613 to standard daunorubicin/cytarabine chemotherapy for newly diagnosed acute myeloid leuke…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML [Phase 1]
Phase 1 trial to assess the safety and tolerability of Ziftomenib in combination with Venetoclax/Azacitidine, Venetoclax alone, or 7+3 with …
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Study of BN104 in the Treatment of Acute Leukemia [Phase 1, Phase 2]
BN104 is being studied in Phase 1/2 trials for acute leukemia; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML [Phase 3]
Phase 3 trial evaluating Revumenib in combination with azacitidine and venetoclax for adults with NPM1-mutated or KMT2A-rearranged acute mye…